Literature DB >> 12970892

Inhibitory effects of docetaxel on expression of VEGF, bFGF and MMPs of LS174T cell.

Xue-Liang Guo1, Geng-Jin Lin, Hong Zhao, Yong Gao, Li-Ping Qian, San-Rong Xu, Li-Na Fu, Qing Xu, Jie-Jun Wang.   

Abstract

AIM: To study the effects of non-cytotoxic concentrations of docetaxel on some important angiogenic factors of LS174T Cells.
METHODS: The non-cytotoxic concentration of docetaxel and the activity of gelatinase were determined with MTT and gelatin zymography respectively, the expression of VEGF(vascular endothelial growth factor), bFGF (basic fibroblast growth factor), MMP (matrix metalloproteinase) 2 and MMP 9 was investigated with RT-PCR and Western blot.
RESULTS: The maximum non-cytotoxic concentration of docetaxel on LS174T Cells was 1.0 ng/ml. Compared with the solvent control group, 0.1, 0.5, 1.0 ng/ml of docetaxel could downregulate the expression of VEGF, bFGF, MMP 2 and MMP 9 and suppress the activity of gelatinase.
CONCLUSION: Our study suggests that the non-cytotoxic concentrations of docetaxel have strong antiangiogenic activity on LS174T Cells, which suggests docetaxel may be a promising antiangiogenic agent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970892      PMCID: PMC4656660          DOI: 10.3748/wjg.v9.i9.1995

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  38 in total

1.  Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Authors:  F Ciardiello; R Caputo; R Bianco; V Damiano; G Fontanini; S Cuccato; S De Placido; A R Bianco; G Tortora
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy.

Authors:  Y C Tang; Y Li; G X Qian
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

3.  The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.

Authors:  C J Sweeney; K D Miller; S E Sissons; S Nozaki; D K Heilman; J Shen; G W Sledge
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

4.  Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer.

Authors:  D H Lau; L Xue; L J Young; P A Burke; A T Cheung
Journal:  Cancer Biother Radiopharm       Date:  1999-02       Impact factor: 3.099

5.  Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa.

Authors:  T André; L Kotelevets; J C Vaillant; A M Coudray; L Weber; S Prévot; R Parc; C Gespach; E Chastre
Journal:  Int J Cancer       Date:  2000-04-15       Impact factor: 7.396

6.  Significance of vascular endothelial growth factor messenger RNA expression in gastric cancer.

Authors:  Hou-Quan Tao; Yan-Zhen Lin; Rui-Nian Wang
Journal:  World J Gastroenterol       Date:  1998-02       Impact factor: 5.742

7.  Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension.

Authors:  Nimer Assy; M Paizi; D Gaitini; Y Baruch; G Spira
Journal:  World J Gastroenterol       Date:  1999-08       Impact factor: 5.742

8.  Recurrence or metastasis of HCC:predictors, early detection and experimental antiangiogenic therapy.

Authors:  Yang-Fu Jiang; Zhi-Hua Yang; Jin-Qun Hu
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

9.  Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.

Authors:  C G Lee; M Heijn; E di Tomaso; G Griffon-Etienne; M Ancukiewicz; C Koike; K R Park; N Ferrara; R K Jain; H D Suit; Y Boucher
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

10.  Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.

Authors:  C H Spiridonidis; L R Laufman; J Jones; V A Rhodes; K Wallace; S Nicol
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

View more
  6 in total

1.  Targeted drug and gene delivery systems for lung cancer therapy.

Authors:  Sneha Sundaram; Ruchit Trivedi; Chandrasekar Durairaj; Rajagopal Ramesh; Balamurali K Ambati; Uday B Kompella
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

2.  Synergistic Beneficial Effect of Docosahexaenoic Acid (DHA) and Docetaxel on the Expression Level of Matrix Metalloproteinase-2 (MMP-2) and MicroRNA-106b in Gastric Cancer.

Authors:  Najibeh Shekari; Mahsa Javadian; Mottahareh Ghasemi; Behzad Baradaran; Masoud Darabi; Tohid Kazemi
Journal:  J Gastrointest Cancer       Date:  2020-03

3.  Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.

Authors:  Lisa D Volk; Michael J Flister; Christopher M Bivens; Alan Stutzman; Neil Desai; Vuong Trieu; Sophia Ran
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

4.  Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model.

Authors:  Sung-Yi Hong; Myun-Hee Lee; Kyung-Sup Kim; Hyun-Cheol Jung; Jae-Kyung Roh; Woo-Jin Hyung; Sung-Hoon Noh; Seung-Ho Choi
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

5.  [Effects of recombinant human endostatin and docetaxel on MMP and its following anti-neoplastic effect under different administration sequences].

Authors:  Jing Yuan; Kai Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-06

Review 6.  Antiangiogenic cancer treatment: The great discovery and greater complexity (Review).

Authors:  Ewa Maj; Diana Papiernik; Joanna Wietrzyk
Journal:  Int J Oncol       Date:  2016-09-26       Impact factor: 5.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.